FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published. Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...

Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is presenting at the American Diabetes Association 73nd Scientific Sessions in Chicago, IL...